Sermorelin therapy should only be used under the guidance of a licensed healthcare provider who can evaluate your medical history and determine whether this treatment is appropriate for you.
All products on this website are intended strictly for laboratory research and in-vitro use only
NASH (Non-Alcoholic Steatohepatitis): Reduces liver fat and improves liver function in individuals with fatty liver disease
Severe or persistent gastrointestinal side effectsincluding intractable nausea, vomiting, or diarrhoea leading to dehydrationmay necessitate stopping the medication
Nikitin D, Lin GA, Campbell JD, Hansen RN, Brouwer E, Chen Y, et al
There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
